Thromboserin Ltd is a UK-based biopharmaceutical company focused on developing and commercialising novel antiplatelet treatments. The company is run by an experienced team with deep roots in the pharmaceutical, academic and healthcare sectors. Our lead product has completed Phase I and is currently being considered for a number of indications where its unique profile offers marked benefits over other newly approved and emerging compounds in this competitive market sector. We expect to achieve proof-of-concept for our first clinical indication in 2017. Business highlights: Market Exclusivity in US and EU - granted and pending patents take IP cover to 2038 and 2025, respectively. High profit potential / low cost business model: low infrastructure, capital efficient business model; providing high value specialist products in response to unmet patient needs. For further information and details of investment opportunities go to www.thromboserin.com
View Top Employees from Thromboserin LimitedWebsite | http://www.thromboserin.com |
Revenue | $3 million |
Employees | 3 (2 on RocketReach) |
Founded | 2007 |
Address | Greens Ct, Midhurst, West Sussex GU29 9NQ, GB |
Technologies |
JavaScript,
HTML,
Google Analytics
+2 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
Competitors | AngioDesign Ltd, IntraBio Ltd, SOLUTIONS OP LTD |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Thromboserin Limited employee's phone or email?
The Thromboserin Limited annual revenue was $3 million in 2024.
Mark Noble is the Chief Medical Officer of Thromboserin Limited.
2 people are employed at Thromboserin Limited.
Thromboserin Limited is based in Midhurst, West Sussex.
The NAICS codes for Thromboserin Limited are [325, 32, 32541, 3254].
The SIC codes for Thromboserin Limited are [283, 28].